Uveitis associated with cancer immunotherapy: long-term outcomes.
Christine FardeauMehdi BencheqrounArielle LevySophie BonninMarie-Adélaïde FerchaudLeila FardeauFlorence CoscasBahram BodaghiBénédicte Lebrun-VignesPublished in: Immunotherapy (2021)
Background: We report the long-term outcome of uveitis associated with cancer immunotherapy (CIT). Methods: This retrospective review included serial patients with CIT-associated uveitis treated using various regimen. Results: Eight patients treated with rituximab (anti-CD20), nivolumab (anti-PD-1), ipilimumab (anti-CTLA-4), vemurafenib and dabrafenib (anti-BRAF), trametinib (anti-MEK) and ibritunib showed uveitis with hypopion (one patient), macular edema (five patients) and choroiditis (two patients). Various regimens of corticosteroid therapy showed a favorable ophthalmological outcome, whether the CIT was continuing or suspended. Conclusion: Local corticosteroid injections in combination with CIT could be suggested as a first-line treatment. This could help to preserve the quality of life without threatening the vital prognosis.
Keyphrases
- end stage renal disease
- juvenile idiopathic arthritis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- ankylosing spondylitis
- prognostic factors
- stem cells
- rheumatoid arthritis
- optical coherence tomography
- signaling pathway
- systemic lupus erythematosus
- mesenchymal stem cells
- cell therapy
- pi k akt
- smoking cessation
- combination therapy